Filters
New drug applications approved by US FDA as of 1-15 October 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Sleep disorders such as insomnia and sleep-associated apnoea appear to contribute to an increased risk of glaucoma, according to a study.
In patients with chronic ischaemic heart disease (IHD), the use of oral nitrates helps lower the risk of open-angle glaucoma (OAG) and primary open-angle glaucoma (POAG), according to a retrospective study.
Lowering the systolic blood pressure (SBP) target to <120 mm Hg compared with <140 mm Hg has a beneficial effect on retinal microvasculature among hypertensive patients with high cardiovascular risk, suggests a recent study.
A study from Singapore underscores the potential of a retinal ageing biomarker derived from retinal photography as a prognostic biomarker for cognitive decline and incident dementia.
Treatment with corticosteroid (CTC) plus conventional disease-modifying antirheumatic drug (C-DMARD) demonstrates an acceptable safety profile and appears to be more efficient than CTC alone in patients with nonanterior sarcoidosis-related uveitis, reports a study.
Infection with the human papillomavirus (HPV) appears to increase the risk of developing glaucoma, a recent study has shown.
New drug applications approved by US FDA as of 1-15 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Compared with intravenous (IV) or oral glucocorticoids (GCs), the use of teprotumumab results in lower risks of mortality and cardiovascular, renal, and infectious outcomes in patients with thyroid eye disease (TED), suggests a study.
A direct selective laser trabeculoplasty (DSLT) falls short of achieving noninferiority to conventional selective laser trabeculoplasty (SLT) in a recent study. However, it is well tolerated and effective in reducing intraocular pressure (IOP) for up to 12 months.
